Search
GLB-001
go.drugbank.com/drugs/DB32795InvestigationalGLB-001 is a orally bioavailable molecular glue degrader targeting casein kinase 1 alpha (CK1a).
C11-12 isoparaffin
go.drugbank.com/drugs/DB11329ApprovedC11-12 isoparaffin is a mixture of branched chain hydrocarbons with 11C or 12C's in the alkyl chain. It is found in cosmetic and personal care products as solvents or skin conditioning agent.
Foscarbidopa
go.drugbank.com/drugs/DB16171ApprovedFoscarbidopa is under investigation in clinical trial NCT04379050 (Extension Study to Evaluate Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Adult
Tamibarotene
go.drugbank.com/drugs/DB04942InvestigationalTamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States.
Teglarinad chloride
go.drugbank.com/drugs/DB05217InvestigationalIn vivo, apoptosis inducer GMX1777 is rapidly converted into GMX1778 through hydrolytic cleavage of a carbonate ester bond. … Although the exact mechanism of action has yet to be fully elucidated, GMX1778 appears to antagonize nuclear factor-kappa B (NF-kB) transcription, resulting in the induction of tumor cell apoptosis.
RAPA-501-Allo
go.drugbank.com/drugs/DB15890InvestigationalRAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed _ex vivo_ in a process that involves de-differentiation and re-differentiation.[L16483]
Hypothiocyanite ion
go.drugbank.com/drugs/DB15309InvestigationalHypothiocyanite ion is under investigation in clinical trial NCT02598999 (Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients).
Trelagliptin
go.drugbank.com/drugs/DB15323InvestigationalTrelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus").
LSZ-102
go.drugbank.com/drugs/DB15362InvestigationalLSZ-102 is under investigation in clinical trial NCT02734615 (Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers).